Nkarta NKTX 深 沪
已收盘 10-30 16:00:00 美东时间
1.56
-0.100
-6.02%
华盛通- 最 高1.66
- 今 开1.66
- 成交量 121.44万股
- 最 低 1.54
- 昨 收 1.66
- 总市值 1.12亿
- 52周最高 3.72
- 市盈率 静 --
- 换手率 1.70%
- 52周最低 1.54
- 委 比 66.28%
- 总股本 7162.48万
- 历史最高 79.16
- 量 比 0.93
- 振 幅 7.23%
- 历史最低 1.28
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nkarta收跌7.1%，成交额416.22万美元
10月28日，Nkarta（NKTX）收跌7.1%，报1.7美元，成交额416.22万美元，市值1.22亿美元。 行情数据 • 开盘价：1.75美元 • 最高价...
10-28 06:57
Nkarta收跌6.74%，成交额320.97万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:59
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics has renamed itself IRulya Therapeutics and will begin trading on Nasdaq under "IRLA" on October 12, 2026. The company has strengthened its leadership with new CEO Brigette Roberts, CFO John Militello, COO Keith Fandrick, and added board members Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise. IRulya is advancing LAM-001, an inhaled rapamycin, in Phase 2 studies for PH-ILD, BOS, and SAPH, supported by $...
10-09 12:00
Nkarta to Participate in September Investor Conferences
Nkarta, Inc. announced its participation in two investor conferences: the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York, and the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026. Both events will feature fireside chats and be webcast live on Nkarta’s website, with replays available for 90 days. Nkarta specializes in developing allogeneic NK cell therapies for autoimmune dise...
09-10 11:00
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
<p>Nkarta, Inc. announced three scientific presentations at ACR Convergence 2026, including two oral presentations on the safety and clinical activity of NKX019 in idiopathic inflammatory myopathy and overall autoimmune indications, and a poster presentation on its activity in systemic sclerosis. NKX019 is an allogeneic, CD19-targeted CAR NK-cell therapy being evaluated in autoimmune diseases. The presentations highlight its safety profile, preli...
09-08 11:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $14.
08-11 20:34
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31) per share from the same period last year.
08-11 05:04
